OCI-AML2 Xenograft Model Service for AML

The OCI-AML2 cell line serves as a highly reliable in vivo platform for modeling acute myeloid leukemia (AML), providing researchers with a sophisticated system to investigate myeloid malignancy progression and therapeutic responses. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision OCI-AML2 Xenograft Model Service designed to produce reproducible, audit-ready datasets that accelerate your AML drug discovery and development pipeline.

Overview of OCI-AML2 Xenograft Model for AML

The OCI-AML2 xenograft model is an established in vivo translational tool widely utilized in hematological oncology research, particularly for the study of AML subtypes characterized by specific MLL rearrangements. By transplanting human OCI-AML2 myeloblastic cells into highly permissive, immunodeficient mouse hosts, this model effectively reproduces the systemic dissemination, aggressive bone marrow infiltration, and distinct peripheral blood pathophysiological profiles seen in clinical AML patients.

Biologically, the OCI-AML2 model is valued for its stable engraftment parameters and proliferative consistency, offering investigators a reliable experimental window for evaluating complex dosing schedules and pharmacokinetic/pharmacodynamic relationships. This model preserves vital human myeloid molecular features, including specific surface antigen profiles and altered intracellular signaling cascades that drive leukemic blast expansion. Consequently, the OCI-AML2 platform is extensively deployed to assess the anti-leukemic potency of small-molecule inhibitors, monoclonal antibodies, and combination therapeutic regimens within a physiologically relevant in vivo environment.

Fig 1. NK cell-mimic nanoparticles are more efficient than NK cells and sTRAIL against acute myeloid leukemia cell lines. (Alizadeh Zeinabad H, et al., 2023)

Cell Line Information: OCI-AML2

The OCI-AML2 cell line was established from the peripheral blood of a patient diagnosed with AML. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a stable myeloblastic phenotype that serves as a robust proxy for modern hematological cancer studies.

Our Services

Workflow of OCI-AML2 Xenograft Model Construction

• Cell Culture & Quality Control: Human OCI-AML2 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (e.g., NSG or NOD/SCID strains to support hematological engraftment) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability OCI-AML2 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific myeloid markers in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 2. OCI-AML2 Xenograft Model Construction Workflow

Case Study - OCI-AML2 Xenograft Model Development

A pre-clinical validation study was conducted using the OCI-AML2 xenograft model to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting myeloid cell survival pathways in AML. Following precision intravenous inoculation of human OCI-AML2 cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals in the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex AML studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our OCI-AML2 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.